Mark Applebaum

Mark Applebaum has contributed to high-risk neuroblastoma research, including work on ALK mutations as neuroblastoma predisposition and therapeutic targets. Neuroblastoma is the most common extracranial solid tumor in children; high-risk disease with MYCN amplification or ALK alterations has poor prognosis and requires intensive multimodal treatment including stem cell transplant and anti-GD2 immunotherapy (dinutuximab). Research on novel targeted approaches for high-risk neuroblastoma addresses critical pediatric oncology needs.